Incyte Corporation (INCY)

NASDAQ
72.16
+0.25(+0.35%)
After Hours
71.79
-0.37(-0.51%)
- Real-time Data
  • Volume:
    1,453,999
  • Day's Range:
    70.76 - 72.50
  • 52 wk Range:
    61.91 - 84.86

INCY Overview

Prev. Close
71.91
Day's Range
70.76-72.5
Revenue
3.32B
Open
71.29
52 wk Range
61.91-84.86
EPS
4.27
Volume
1,453,999
Market Cap
15.98B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,486,976
P/E Ratio
17.01
Beta
0.64
1-Year Change
-5.43%
Shares Outstanding
221,505,011
Next Earnings Date
01 Nov 2022
What is your sentiment on Incyte?
or
Market is currently closed. Voting is open during market hours.

Incyte Corporation Company Profile

Incyte Corporation Company Profile

Employees
1773

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuySellStrong SellStrong Sell
SummaryStrong BuyStrong BuySellStrong SellStrong Sell